Analysis of the GSTF8-L and GSTF8-S proteins demonstrated that GSTF8-L is solely targeted to plastids, whereas GSTF8-S is cytoplasmic (Thatcher et al., 2007)
Because BPC-157s target receptor has not been conclusively identified, researchers frequently describe its activity using hypothesis-driven language rather than confirmed mechanistic claims
Or to frame it differently, researchers using oral acetate BPC-157 may have been receiving only a fraction of the intended dose, which could explain the inconsistent results that some users reported with oral BPC-157 protocols
New England Journal of Medicine, 370(22), 20632066
Recalls & Warnings May 24, 2013 Maker of Neuropathic Pain Product Warned For Drug Claims, Misbranding On April 11, 2013, the FDA issued a warning letter to Realm Labs, LLC, following a review of the companys websites which found statements made about its NeuRemedy products to be drug claims